8-K 1 l01347ae8vk.txt SHEFFIELD PHARMACEUTICALS 8-K ================================================================================ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): JUNE 6, 2003 SHEFFIELD PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) DELAWARE (State or other jurisdiction of incorporation) 1-12584 13-3808303 (Commission File Number) (I.R.S. Employer Identification No.) 3136 WINTON ROAD, SUITE 201, ROCHESTER, NEW YORK 14623 (Address of principal executive offices) (Zip Code) (585) 292-0310 (Company's telephone number, including area code) (NOT APPLICABLE) (Former name or former address, if changed since last report) ================================================================================ ITEM 3. BANKRUPTCY OR RECEIVERSHIP On June 6, 2003, Sheffield Pharmaceuticals, Inc. announced that it has ceased operations and filed a bankruptcy petition under Chapter 7 of the United States Bankruptcy Code. The petition was filed on June 6, 2003 with the United States Bankruptcy Court for the Western District of New York. As a result of the initiation of bankruptcy proceedings, Sheffield Pharmaceuticals, Inc. expects that it will cease filing periodic reports under the Securities Exchange Act of 1934. SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SHEFFIELD PHARMACEUTICALS, INC. June 6, 2003 By: /s/ Thomas M. Fitzgerald ----------------------------------------- Thomas M. Fitzgerald President and Chief Executive Officer